Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, David Cameron, Seock‐Ah Im et al.|New England Journal of Medicine|2022Cited by 2.5k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine TherapyGeorge W. Sledge, Antonio Llombart‐Cussac, Masakazu Toi et al.|Journal of Clinical Oncology|2017Cited by 1.7k
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trialElizabeth A. Mittendorf, Nadia Harbeck, Hong Zhang et al.|The Lancet|2020Cited by 1.1k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast CancerSeock‐Ah Im, Debu Tripathy, Yen‐Shen Lu et al.|New England Journal of Medicine|2019Cited by 1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trialDebu Tripathy, Yen‐Shen Lu, Seock‐Ah Im et al.|The Lancet Oncology|2018Cited by 1k